Evotec Partners with CRTD to Discover Novel Therapies for Retinal Diseases
Evotec has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden (CRTD) to discover novel small molecule candidates for retinal diseases. CRTD is a recognised leader in understanding the biology of stem cells to develop new therapies for neurodegenerative and haematological diseases.
According to a media release, under the terms of the collaboration, Evotec will leverage CRTD's expertise in stem cell-based retinal disease modelling and will apply its induced pluripotent stem cell (iPSC) technology platform to identify promising drug candidates for potential clinical development.
The global retinal dystrophy market - which includes both rare genetic diseases as well as glaucoma, AMD and diabetic retinopathy - represents millions of patients. Whilst cell replacement and gene therapies will likely play an important role in the future, there continues to be a need for small molecule treatments as both monotherapy and in combination with other therapies. Through the use of patient-derived iPSCs and subsequent differentiation into various cell types contained in the retina, the collaboration aims to build highly relevant "disease-in-a-dish" models that may lead to potential cures for the major causes of blindness.
Prof. Ezio Bonifacio, Director, CRTD, said: "As an academic institution where our employees and students hail from more than 30 different countries, CRTD was founded on scientific principles that support strong interdisciplinary research on a global scale. Due to this, we recognise the importance of generating more productive relationships between academia and industry across all countries. As a leading discovery alliance partner, we believe that Evotec shares our bold vision and are very pleased to collaborate with the company under its EVT Innovate platform. We look forward to working closely with our colleagues at Evotec to discover new therapeutic approaches for retinal diseases and laying the groundwork for better overall human health."
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very pleased to enter into this collaboration with CRTD in the field of retinal diseases, which constitutes a market of enormous unmet medical need. CRTD is a world leader in stem cell-derived modelling of retinal disease and thus fits perfectly into our strategy to continue to build and expand Evotec's unique iPSC based drug discovery platform."
Financial terms of the collaboration were not disclosed.
((Comments on this story may be sent to firstname.lastname@example.org))
THE DAILY VIEW
Tea Forté Introduces ‘Matcha’ Collection
Convenience meets tradition in Tea Forté’s new Ceremonial Matcha Bowl Set and the Matcha Single Steeps.
The company said its spring harvested, shade grown, stone ground, organic matcha tea is best served in a centuries-old Japanese tea ceremony called chanoyu: a preparation technique known for its centering meditative qualities.
"The launch of Tea Forté's Matcha collection represents our continued commitment to wellness and cultivating all the potential mental and physical health benefits of tea," says Tea Forté CEO Michael Gebrael. "In addition to our high quality Pure Matcha, we've also blended four distinct flavored Matcha varieties. Prepackaged in pouches measured out for a single serving, our Single Steeps Matcha is ideal for the office, travel, or to keep with you for a boost anytime."
Tea Forté noted its handcrafted ceremonial tea bowl, handmade bamboo whisk and measuring ladle “encourages serene enjoyment of our premium Kosher, gluten-free and vegan matcha blends.” These include: Pure Matcha, Chocolate Matcha, Coconut Matcha, Ginger Matcha, and Chai Matcha.
According to a release, in addition to its distinctive taste, matcha is prized for its health benefits. Steeped green tea contains only the antioxidants that can be extracted in water, while with matcha, the whole leaf is consumed.
Available now in select stores and online at teaforte.com.
Expedia.com has released a year-end look at U.S. traveler behavior and trends for 2017, analyzing data to identify the most in-demand destinations, hotels, activities and more.
Among other insights, the roundup revealed:
- Labor Day was the busiest weekend for car rental
- Disney Theme Parks topped the list of things to do
- The average hotel stay was two nights
- Top destinations based on 2017 air travel included major global cities like New York, London and Bangkok
- Popular tourist destinations included Orlando, Cancun and Las Vegas